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graphic access to TB diagnostic and treatment facilities 
might inﬂ  uence pre-treatment loss to follow-up rates. 
Such information would be useful to assess and im-
prove programme performance. Fiji is a Paciﬁ  c Island 
country that has been implementing the DOTS strat-
egy since 1997.9 There are an estimated 23 TB cases 
per 100  000 population, of which ~10/100  000 are 
smear-positive PTB cases. 
We therefore 1) report pre-treatment loss to follow-
up rates over a 10-year period (2001–2010) in Fiji, and 
2) examine if patients’ age, sex and geographic origin 
are associated with the observed shortcomings in the 
health services.
METHODS
Study design 
This was a retrospective review of routine NTP data.
Study setting and sites 
Fiji occupies an archipelago of about 322 islands, of 
which 106 have permanent inhabitants, and 522 islets. 
The country has two major islands, Viti Levu and Vanua 
Levu, which account for 87% of the population. In 2008, 
the country had an estimated population of 840  000. 
Fiji is divided into four geographic divisions, namely 
Central, Eastern, Northern and Western (Figure).
Until 2010, there were only two DOTS centres pro-
viding TB registration and treatment in the country: 
the P J Twomey Hospital and the Lautoka Hospital, lo-
cated respectively in the Central and Western Divi-
sions of Fiji. There are four laboratories in the country 
that provide sputum smear microscopy services: these 
include the above-mentioned two centres, the Colo-
nial War Memorial Hospital (the largest hospital in the 
country, located in the Central Division) and the La-
basa Hospital (located in the Northern Division). TB 
diagnosis and treatment cannot be obtained anywhere 
else in the country other than at these centres.
Laboratory diagnosis and registration 
of pulmonary tuberculosis patients 
A person with a cough of >2 weeks is considered a ‘pos-
sible case of TB’, and is required to submit three spu-
tum specimens for smear microscopy. Smear-positive 
PTB is diagnosed on the basis of one or more acid-fast 
tubercle bacilli found in at least one sputum smear sam-
ple. All persons who undergo sputum smear examina-
tion are recorded in the laboratory register, as are the 
results of the sputum smear. All sputum smear-positive 
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Setting:  All tuberculosis (TB) diagnostic and treatment 
centres in Fiji.
Objectives: To report on pre-treatment loss to follow-up 
rates over a 10-year period (2001–2010) and to examine 
if patients’ age, sex and geographic origin are associated 
with the observed shortcomings in the health services.
Methods: A retrospective review of routine programme 
data reconciling TB laboratory and treatment registers.
Results: A total of 690 sputum smear-positive TB patients 
were diagnosed in the laboratory, of whom 579 (84%) 
were started on anti-tuberculosis treatment—an overall 
pre-treatment loss to follow-up of 111 (16%). Peak loss 
to follow-up rates were seen in 2003, 2004 and 2010. 
Pre-treatment losses were all aged ⩾15 years. In the 
Western Division of Fiji, 33% of sputum-positive patients 
were declared pre-treatment loss to follow-up; this divi-
sion had over five times the risk of such an adverse out-
come compared to the Central Division (OR 5.2, 95%CI 
3.1–8.9, P < 0.0001).
Conclusion: This study has identified an important short-
coming in programme linkage, communication and feed-
back between TB diagnostic and treatment services, lead-
ing to high pre-treatment loss to follow-up rates. This 
negatively influences TB services, and ways to rectify this 
situation are discussed. 
G
lobally, under the National Tuberculosis Pro-
gramme (NTP), a patient who does not appear 
in the tuberculosis (TB) treatment register after having 
been diagnosed with sputum smear-positive pulmonary 
TB (PTB), and thus is not initiated on anti-tuberculosis 
treatment, is known as a ‘pre-treatment loss to follow-
up’.1 These patients were previously referred to as ‘ini-
tial defaulters’.2 From the perspective of the TB ser-
vices, ‘pre-treatment loss to follow-up’ is important for 
two main reasons. First, untreated smear-positive PTB 
patients are infectious and may transmit TB to others 
in the community, constituting an important public 
health risk. Second, if and when such patients are 
identiﬁ  ed in the health services, their illness is likely 
to have progressed and this can negatively inﬂ  uence 
their treatment outcome.
Previous studies in Africa and Asia have reported 
pre-treatment loss to follow-up rates of 5% to 25%, 
and various associated factors have been identiﬁ  ed.3–8 
In the Paciﬁ  c Islands, there is no published informa-
tion about the extent of this problem, nor whether 
p  atients’ socio-demographic characteristics and geo-
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TB cases are then supposed to be referred to one of the two TB 
treatment centres, recorded in the TB treatment register and 
started on anti-tuberculosis treatment. 
Study population and identification 
of pre-treatment loss to follow-up 
All patients found to be sputum smear-positive in the sputum lab-
oratory registers of the four laboratories from 2001 to 2010 were 
included in the study. The TB treatment registers were carefully 
reconciled with the laboratory registers. A patient who was sputum-
positive on the laboratory register but not found on the TB treat-
ment register was declared as ‘pre-treatment loss to follow-up’. 
Data and statistical analysis
The following data were collected from the laboratory registers: 
year, socio-demographic characteristics (including name) and geo-
graphic residence. Data were entered into EpiData (EpiData Asso-
ciation, Odense, Denmark) and cross-checked for consistency; 
discrepancies were corrected by referring to the original records. 
Risk of pre-treatment loss to follow-up was measured using crude 
odds ratios (ORs) and their 95% conﬁ  dence intervals (CIs). The 
level of signiﬁ  cance was set at 5%. 
Ethics approval
Ethical approval was obtained from the Fiji National Research Eth-
ics Committee and the Ethics Advisory Group of the International 
Union Against Tuberculosis and Lung Disease, Paris, France.
RESULTS
During the period 2001–2010, a total of 690 sputum smear-
positive TB patients were diagnosed in the laboratory, of whom 
579 (84%) were started on anti-tuberculosis treatment—an overall 
pre-treatment loss to follow-up of 111 (16%). The trend in pre-
treatment loss to follow-up over the 10-year period is shown in 
Table 1. Peak loss-to-follow-up rates were seen in 2003, 2004 and 
2010. Patients lost to follow-up were all aged ⩾15 years (Table 2). 
From the Western Division of Fiji, 33% of sputum-positive pa-
tients were declared pre-treatment loss to follow-up and had over 
ﬁ  ve times the risk of such an outcome compared to the Central 
Division (OR 5.2, 95%CI 3.1–8.9, P < 0.0001).
FIGURE  Map of Fiji showing the geographic divisions.Public Health Action Pre-treatment loss to follow-up  140
DISCUSSION
This ﬁ  rst study from the Paciﬁ  c Islands to assess pre-treatment 
loss to follow-up rates over a decade shows that about two in 
10 individuals with infectious TB were not placed on anti-
t  uberculosis treatment. The Western Division of Fiji had the high-
est rates. 
The strengths of this study are that we included country-wide 
data that come from the routine programme setting and are thus 
likely to reﬂ  ect the operational reality on the ground, and data 
were rigorously cross-checked and validated for accuracy. We also 
adhered to STROBE (Strengthening the Reporting of Observa-
tional Studies in Epidemiology) guidelines on reporting of obser-
vational studies.10 
The limitations are that we examined risk of loss to follow-up 
using a limited number of variables and we did not trace patients 
to verify whether they had started anti-tuberculosis treatment 
elsewhere. However, in Fiji, as anti-tuberculosis treatment is only 
available at centres included in this study, it is unlikely that pa-
tients could have accessed care elsewhere. Our results are thus 
likely to be realistic.
The programme implications of these ﬁ  ndings are two fold. 
First, a considerable proportion of infectious TB cases are not be-
ing placed on anti-tuberculosis treatment, and this constitutes a 
public health risk. Second, cohort reporting of programme out-
comes that excludes this group will portray an incorrect picture of 
programme success, and this is a shortcoming.
We propose a number of ways to correct the current situation. 
First, the TB laboratory register should include the detailed ad-
dress and telephone numbers of patients with TB to allow tracing 
and follow-up. Second, the laboratory and treatment registers 
should be reconciled on a regular, scheduled basis (e.g., every 
2 weeks) to allow early detection of pre-treatment loss to follow-
up. To facilitate this process, the laboratory register number 
should also be entered into the TB patient treatment register and 
vice versa. Third, quarterly TB reporting should include the num-
ber and proportion of pre-treatment loss to follow-up patients. 
This will allow the NTP to be vigilant and to act in time. Finally, 
there is a need for speciﬁ  c investigations in the Western Division 
of Fiji to evaluate the reasons for the higher rates of pre-treatment 
loss to follow-up here.
In conclusion, this study has identiﬁ  ed an important short-
coming in programme linkage, communication and feedback be-
tween TB diagnostic and treatment services leading to high pre-
treatment loss to follow-up rates. This negatively inﬂ  uences TB 
services, and urgent steps are being taken to rectify this situation.
References
 1  Zachariah R, Harries A D, Srinath S, et al. Language in tuberculosis services: 
can we change to patient-centred terminology and stop the paradigm of 
blaming the patients? Int J Tuberc Lung Dis 2012; 16: 714–717.
 2  Harries A D, Rusen I D, Chiang C-Y, Hinderaker S G, Enarson D A. Register-
ing initial defaulters and reporting on their treatment outcomes. Int J Tuberc 
Lung Dis 2009; 13: 801–803.
 3  Botha E, den Boon S, Lawrence K-A, et al. From suspect to patient: tubercu-
losis diagnosis and treatment initiation in health facilities in South Africa. 
Int J Tuberc Lung Dis 2008; 12: 936–941.
 4  Botha E, Den Boon S, Verver S, et al. Initial default from tuberculosis treat-
ment: how often does it happen and what are the reasons? Int J Tuberc Lung 
Dis 2008; 12: 820–823.
 5  Buu T N, Lönnroth K, Quy H T. Initial defaulting in the National Tuberculo-
sis Programme in Ho Chi Minh City, Vietnam: a survey of extent, reasons 
and alternative actions taken following default. Int J Tuberc Lung Dis 2003; 
7: 735–741.
 6  Nyirenda T, Harries A D, Banerjee A, Salaniponi F M. Registration and treat-
ment of patients with smear-positive pulmonary tuberculosis. Int J Tuberc 
Lung Dis 1998; 2: 944–945.
 7 Sai Babu B, Satyanarayana A V V, Venkateshwaralu G, et al. Initial default 
among diagnosed sputum smear-positive pulmonary tuberculosis patients in 
Andhra Pradesh, India. Int J Tuberc Lung Dis 2008; 12: 1055–1058.
 8  Squire S B, Belaye A K, Kashoti A, et al. ‘Lost’ smear-positive pulmonary tu-
berculosis cases: where are they and why did we lose them? Int J Tuberc 
Lung Dis 2005; 9: 25–31.
 9 National Tuberculosis Control Program. Monitoring and evaluation plan. 
Suva, Fiji: Fiji Ministry of Health, 2010.
  10  Elm E V, Altman D G, Egger M, Pocock S J, Gotzche P C, Vandenbroucke J P. 
The Strengthening the Reporting of Observational Studies in Epidemiology 
(STROBE) Statement: guidelines for reporting observational studies. Bull 
World Health Organ 2007; 85: 867–872.
TABLE 1  Pre-treatment loss to follow-up in smear-positive 
pulmonary TB patients, Fiji, 2001–2010
Year 
TB patients in 
laboratory register
n
Patients in TB 
treatment register
n
Pre-treatment 
loss to follow-up
n (%)
2001  62  50  12  (11)
2002  86  75  11  (10)
2003  65  49  16  (14)
2004  64  45  19  (17)
2005  59  47  12  (11)
2006  72  61  11  (10)
2007  59  52  7  (6)
2008  77  72  5  (5)
2009  59  55  4  (4)
2010  87  73  14  (13)
 Total 690 579 111  (16)
TB = tuberculosis.
TABLE 2  Risk factors associated with pre-treatment loss to 
follow-up, Fiji, 2001–2010 
Variable
Total 
patients 
diagnosed
n
Patients 
in TB 
treatment 
register
n (%)
Pre-treatment 
loss to 
follow-up
n (%) OR (95%CI)
Age, years
  <15   13  13  (100)   0  NA
  ⩾15  677 566 (84) 111 (16)
Sex
  Male 383 318 (83)   65 (17) Referent
  Female 311 256 (85)   46 (15) 0.9 (0.6–1.3)
  Sex  not  recorded   5   5  (100)   0  NA
Geographic division
  Central  292 267 (91)   25 (9) Referent
  Eastern   64  58  (91)   6  (9) 1.1  (0.4–3.0)
  Western 205 138 (67)   67 (33) 5.2 (3.1–8.9)*
  Northern 118 106 (90)   12 (10) 1.2 (0.5–2.6)
  Others*  11  10  (91)   1  (9) NA
* From other Pacific islands.
TB = tuberculosis; OR = odds ratio; CI = confidence interval; NA = not available.Public Health Action Pre-treatment loss to follow-up  141
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  Contexte  :    Tous les centres de diagnostic et de traitement de la tu-
berculose (TB) aux Iles Fiji.
Objectif  :  Signaler les taux de pertes de suivi avant traitement sur une 
période de 10 ans (2001–2010) et examiner dans quelle mesure l’âge, 
le sexe et l’origine géographique des patients sont en association avec 
cette déficience du service de santé.
Méthodes  :  Revue rétrospective des données de routine du programme 
avec recoupement des registres de laboratoire et de traitement.
Resultats  :    Au total, 690 patients TB à frottis positif des crachats ont 
été diagnostiqués au laboratoire, parmi lesquels 579 (84%) ont été 
mis sous traitement antituberculeux, ce qui fournit une perte globale 
du suivi avant traitement de 111 sujets (16%). Des pics des taux de 
perte de suivi ont été observés en 2003, 2004 et 2010. Les pertes 
avant traitement concernaient des patients âgés de ⩾15 ans. Dans la 
Division Ouest des Iles Fiji, 33% des patients à frottis positif des cra-
chats ont été déclarés comme perdus de vue avant traitement, et 
dans cette division le risque de ce résultat défavorable a été cinq 
fois supérieur à celui de la Division Centrale (OR 5,2 ; IC 3,1–8,9 ; P < 
0,0001).
Conclusion  :    Cette étude a identifié une déficience importante dans 
le recoupement des programmes, la communication et le retour 
d’information entre les services de diagnostic et de traitement de la 
TB, entrainant des taux élevés de perte de suivi avant traitement. Ceci 
influence les services TB de façon négative. La discussion porte sur les 
moyens de rectifier la situation. 
Marco de referencia: Todos los centros de diagnóstico y tratamiento 
de la tuberculosis (TB) en Fiji.
Objetivo: Documentar las tasas de pérdida temprana de pacientes 
con TB durante el seguimiento, antes de comenzar el tratamiento, en 
un período de 10 años (del 2001 al 2010) y analizar si la edad, el 
sexo y la procedencia geográfica de los pacientes se correlacionan 
con estas fallas en el servicio de salud. 
Métodos: Se llevó a cabo un examen retrospectivo de los datos cor-
rientes del programa y se buscó la correspondencia de la infor-
mación del laboratorio de TB con los datos del registro de trata-
miento antituberculoso. 
Resultados: En el laboratorio se diagnosticaron 690 casos de TB 
con baciloscopia positiva, de los cuales 579 comenzaron el trata-
miento antituberculoso (84%), lo cual corresponde a una pérdida 
de 111 casos durante el seguimiento temprano antes del tratamiento 
(16%). Las proporciones más altas de pérdida se presentaron en el 
2003, el 2004 y el 2010; los casos perdidos correspondieron a paci-
entes ⩾ de 15 años de edad. En la división occidental de Fiji se de-
claró una pérdida de 33% de los pacientes con baciloscopia positiva 
antes de comenzar el tratamiento; esta división presentó un riesgo 
cinco veces mayor de desenlace clínico desfavorable en comparación 
con la división central (cociente de posibilidades 5,2; intervalo de 
confianza del 95% de 3,1 a 8,9; P < 0,0001).
Conclusión: En el presente estudio se pusieron en evidencia graves 
deficiencias al comparar los datos del programa, la comunicación y la 
retroalimentación entre los servicios de diagnóstico y tratamiento de 
la TB, lo cual da origen a altas tasas de pérdida temprana de paci-
entes durante el seguimiento, antes comenzar el tratamiento. Esta 
situación tiene repercusiones negativas en el desempeño de los servi-
cios de atención de la TB. En el artículo se analizan los mecanismos 
que permitirían rectificar estas insuficiencias.